Vertex Reports First-Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq end lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Vertex Pharma (VRTX) Tops Q1 EPS by 16c, Revenues Beat; Affirms FY19 Revenue Guidance Below Consensus
April 30, 2019 4:04 PM EDTVertex Pharma (NASDAQ: VRTX) reported Q1 EPS of $1.14, $0.16 better than the analyst estimate of $0.98. Revenue for the quarter came in at $857 million versus the consensus estimate of $850.93 million.
First-quarter 2019 product revenues of $857 million, a 34% increase compared to $638 million in 2018-First-quarter 2019 GAAP operating income increased 115% to $277 million;... More